Loading the comparison…
Loading the comparison…
Cognitive & Mood
A three-amino-acid Khavinson 'bioregulator' aimed at the brain.
Cognitive & Mood
A small angiotensin-derived compound with striking rat memory data and no human trials.
Pinealon is not FDA-approved and rated 2/5 for evidence; Dihexa is not FDA-approved and rated 2/5. They have a similar amount of human evidence. Both are banned in sport by WADA. Both are used for cognitive & mood goals.
| Compare | Pinealon A three-amino-acid Khavinson 'bioregulator' aimed at the brain. | Dihexa A small angiotensin-derived compound with striking rat memory data and no human trials. |
|---|---|---|
| Category | Cognitive & Mood | Cognitive & Mood |
| Evidence | 2/5Cell and animal studies from the developing group; one small uncontrolled human cohort. No placebo-controlled trials. | 2/5Animal and cell data from one main research group. No published human trials. A related HGF-boosting drug from the same lineage (fosgonimeton) missed its main goal in a Phase 2/3 Alzheimer's trial. |
| FDA status | Not FDA-approved | Not FDA-approved |
| WADA (sport) | Banned | Banned |
| Also known as | EDR, Glu-Asp-Arg | PNB-0408, N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide |
| How it works | Proposed to enter cells and interact with DNA to influence gene activity, and to reduce oxidative stress in neurons. These ideas come mainly from the developers' lab and are not independently confirmed. | Binds hepatocyte growth factor (HGF) and strengthens its signal through the c-Met receptor, promoting new synapses and dendritic spines. HGF/c-Met is also a well-known cancer-growth pathway. |
| Half-life | Not well characterized; likely short | Not established in humans |
| Commonly reported doses |
|
|
| Route | Subcutaneous | Oral or transdermal (most common); some inject |
| Good once mixed | ~30 days in the fridge | ~14 days in the fridge |
| Top side effects |
|
|
| Lowest research-listing price per mg | $3.00 (10 mg vial, 40% off) | $3.60 (10 mg vial, 40% off) |
| Latest lab purity | 99.90% (lot PIN0002) | 99.54% (lot DHX0001) |
Want a third? Add another peptide. Doses are commonly reported ranges, not recommendations.
Free for ChatGPT and Claude
Connect MyPeps to ChatGPT or Claude and ask follow-ups about Pinealon and Dihexa. It answers from these same pages, with links back here.
Pinealon is not FDA-approved and rated 2/5 for evidence; Dihexa is not FDA-approved and rated 2/5. They have a similar amount of human evidence. Both are banned in sport by WADA. Both are used for cognitive & mood goals.
Pinealon: Not FDA-approved. Dihexa: Not FDA-approved. Regulations change, so confirm with the FDA.
Pinealon is rated 2 out of 5: Cell and animal studies from the developing group; one small uncontrolled human cohort. No placebo-controlled trials. Dihexa is rated 2 out of 5: Animal and cell data from one main research group. No published human trials. A related HGF-boosting drug from the same lineage (fosgonimeton) missed its main goal in a Phase 2/3 Alzheimer's trial. The scale is explained on our methodology page.
Pinealon is banned by WADA, by name or as part of a named class. Dihexa is banned by WADA, by name or as part of a named class.